Business & Academia Join Forces To Study Magic Mushroom Therapy For IBS Patients
Psychedelics company Tryp Therapeutics Inc.
Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs.
New Sublingual Psychedelic Drug Candidate Created For Depression And Anxiety In Alzheimer’s
Psychedelics R&D biotech Biomind Labs Inc.
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism’s Genetic Cause Receives Approval
The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a No Objection letter and is set to proceed with the first-ever Phase 2a clinical trial on the magic mushrooms therapy for this condition.
This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage
Short-acting psychedelics biotech company Small Pharma Inc.
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK’s Research Support And More
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing
Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors (SSRIs) and proprietary lead DMT candidate SPL026 in patients with Major Depressive Disorder (MDD).
Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment
Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug candidates, according to CEO Adi Zuloff-Shani.
FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder
After a full review of healthcare provider Ehave Inc.'s (OTC Pink: EHVVF) IND application, the U.S.
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022.
Financials showed: